The latest price target for SAB Biotherapeutics (NASDAQ:SABS) was reported by Chardan Capital on November 7, 2024. The analyst firm set a price target for $25.00 expecting SABS to rise to within 12 months (a possible 725.55% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for SAB Biotherapeutics (NASDAQ:SABS) was provided by Chardan Capital, and SAB Biotherapeutics maintained their buy rating.

There is no last upgrade for SAB Biotherapeutics

The last downgrade for SAB Biotherapeutics Inc happened on October 5, 2023 when Ladenburg Thalmann changed their price target from N/A to N/A for SAB Biotherapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SAB Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SAB Biotherapeutics was filed on November 7, 2024 so you should expect the next rating to be made available sometime around November 7, 2025.

While ratings are subjective and will change, the latest SAB Biotherapeutics (SABS) rating was a maintained with a price target of $25.00 to $25.00. The current price SAB Biotherapeutics (SABS) is trading at is $3.03, which is out of the analyst’s predicted range.